Alector has significant cash reserves but faces high cash burn, with no immediate catalysts and uncertain prospects for its ...

Cantor Fitzgerald reiterated their overweight rating on shares of Alector (NASDAQ:ALEC – Free Report) in a research report ...

Vigil Neuroscience's stock dropped after Alector's AL002 failed in Alzheimer's, raising concerns about VG-3927's efficacy.

Alector (NASDAQ:ALEC – Free Report) had its price target reduced by HC Wainwright from $35.00 to $7.00 in a report published on Friday, MarketBeat.com reports. They currently have a buy rating on the ...

On Friday, Alector Inc (ALEC) stock saw a modest uptick, ending the day at $2.6 which represents a slight increase of $0.05 or 1.96% from the prior close of $2.55. The stock opened at $2.55 and ...

US clinical stage biotech Alector saw its shares tumble 35% to $2.57 by close of trading yesterday, as it announced ...

H.C. Wainwright analyst Andrew Fein lowered the firm’s price target on Alector (ALEC) to $7 from $35 and keeps a Buy rating ...

On Wednesday, Alector Inc (ALEC) stock saw a decline, ending the day at $2.55 which represents a decrease of $-0.02 or -0.78% from the prior close of $2.57. The stock opened at $2.6 and touched a low ...

On a routine basis in recent years, headlines about layoffs in the biopharma industry have surfaced as companies large and ...

Mizuho Securities analyst Graig Suvannavejh has maintained their bullish stance on VIGL stock, giving a Buy rating yesterday.Don't Miss our ...

And the first IPO without a fixed share price since the shutdown ended late last month was from Alector, a biotech that is aiming to find new treatments for dementia. Alector fell on its trading ...